Advanced Solid Tumor

A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fruquintinib in Advanced Solid Tumors

  • Study nickname: Hutchinson
  • Line: 2nd-4th line of therapy
  • Target Population: Patients with stage IV, locally advanced or metastatic solid malignancy (except squamous NSCLC) who have progressed on approved systemic tx; patients for whom no effective thearpy or standard of care exists
  • Study drug: Fruquintinib
  • Principal Investigator: Thomas Stanton, MD
  • For more information, please contact the lead coordinator, Sabine Ucik, at or (707) 521-3830

Our Locations